BioCryst Pharmaceuticals, Inc.
BCRX
$8.80
$0.222.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 156.41M | 406.56M | 159.40M | 163.35M | 145.53M |
| Total Other Revenue | -- | -- | -- | -- | 11.29M |
| Total Revenue | 156.41M | 406.56M | 159.40M | 163.35M | 145.53M |
| Cost of Revenue | 65.70M | 48.35M | 46.79M | 46.18M | 41.84M |
| Gross Profit | 90.72M | 358.21M | 112.61M | 117.17M | 103.70M |
| SG&A Expenses | 94.55M | 91.51M | 83.01M | 87.38M | 82.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 160.25M | 139.86M | 129.80M | 133.57M | 124.31M |
| Operating Income | -3.84M | 266.70M | 29.59M | 29.79M | 21.23M |
| Income Before Tax | -720.81M | 248.02M | 12.13M | 6.49M | 758.00K |
| Income Tax Expenses | 1.00M | 2.17M | -769.00K | 1.40M | 726.00K |
| Earnings from Continuing Operations | -721.81M | 245.85M | 12.90M | 5.09M | 32.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -721.81M | 245.85M | 12.90M | 5.09M | 32.00K |
| EBIT | -3.84M | 266.70M | 29.59M | 29.79M | 21.23M |
| EBITDA | -2.78M | 267.55M | 31.57M | 30.12M | 21.56M |
| EPS Basic | -2.98 | 1.17 | 0.06 | 0.02 | 0.00 |
| Normalized Basic EPS | -0.06 | 0.77 | 0.04 | 0.03 | 0.00 |
| EPS Diluted | -2.98 | 1.13 | 0.06 | 0.02 | 0.00 |
| Normalized Diluted EPS | -0.06 | 0.74 | 0.04 | 0.03 | 0.00 |
| Average Basic Shares Outstanding | 242.26M | 210.97M | 210.18M | 209.52M | 208.88M |
| Average Diluted Shares Outstanding | 242.26M | 219.26M | 219.89M | 219.89M | 215.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |